GlassScriptPhysician profile
Lacy M Moore
NPI 1457682874
$1,918.68
in general payments reported to CMS, 2019-2025
20 companies · $783 in 2025
The $783 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $244 · 2023: $282 · 2024: $402 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.57 | 2021-2025 | |
| Lilly USA, LLC | $307.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $276.97 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $212.34 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Xeris Pharmaceuticals, INC. | $191.94 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $95.91 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $92.95 | 2021-2023 | |
| Axsome Therapeutics, INC. | $79.11 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $66.17 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $42.66 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.97 | 2024 | Lokelma, Farxiga |
| Exact Sciences Corporation | $28.39 | 2023-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $20.80 | 2025 | Xhance, Nuzyra |
| Boston Scientific Corporation | $18.90 | 2025 | Wavewriter Alpha Prime 16 |
| Esperion Therapeutics, INC. | $17.96 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.25 | 2023 | Rexulti |
| Insulet Corporation | $16.45 | 2023 | Omnipod |
| Philips North America LLC | $15.36 | 2025 | Vest Therapy Und |
| Janssen Pharmaceuticals, INC | $14.42 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $12.67 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.